A preliminary study on the establishment of a subcutaneous allergen-specific immunotherapy center.
10.3760/cma.j.cn112150-20230814-00095
- Author:
Bing LU
1
;
Fei YE
2
;
Guang Hui LIU
1
;
Qing XIE
1
;
Liang CHEN
1
;
Shu Chen ZHANG
3
Author Information
1. Department of Allergy, Union Shenzhen Hospital, Huazhong University of Science and Technology, Shenzhen 518000, China.
2. Department of Allergy,Zhongshan City People's Hospital, Zhongshan 528499, China.
3. Department of Allergy, Zhongnan Hospital,Wuhan University, Wuhan 430071, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Allergens/therapeutic use*;
Quality of Life;
Immunotherapy;
World Health Organization
- From:
Chinese Journal of Preventive Medicine
2023;57(12):1942-1948
- CountryChina
- Language:Chinese
-
Abstract:
Allergic diseases can notably affect a patient's quality of life. World Health Organization (WHO) has identified these diseases as one of the key areas for research and prevention in the 21st century. Currently, allergen-specific immunotherapy is viewed as a potential treatment approach that could modify the natural progression of allergic diseases, thus being recognized as a crucial tactic in their prevention and treatment. Nonetheless, the broad implementation of allergen-specific immunotherapy in clinical settings continues to confront challenges. One significant issue is the absence of standardized centers for subcutaneous allergen-specific immunotherapy. This article presents several perspectives and recommendations for establishing a standardized subcutaneous allergen-specific immunotherapy center.
